New Ray Medicine International Holding Ltd. (6108.HK)
Full history for every metric is available with a Kvantra account
New Ray Medicine International Holding Ltd. (6108.HK)
No price history available.
Key financial summary
Financials in HKDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HKD m | - | - | - | - | - | - | - | - |
| Operating profit | HKD m | - | |||||||
| Net profit | HKD m | - | - | - | - | - | - | - | - |
| EPS reported | HKD | - | |||||||
| Operating cashflow per share | HKD | - | |||||||
| Capex per share | HKD | - | |||||||
| FCF per share | HKD | - | |||||||
| Free cash flow | HKD m | - | |||||||
| Net debt | HKD m | - | |||||||
| Book value equity | HKD m | - | |||||||
| Book value per share | HKD | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | HKD | - |
Financial summary
Financials in HKDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
New Ray Medicine International Holding Ltd. is an investment company, which engages in the distribution and trading of pharmaceutical products. It operates through the following business segments: Injection Drugs; Capsule and Granule Drugs; Tablet Drugs; Marketing and Promotion Services; and Others. The Injection Drugs segment includes the trading of injection drugs. The Capsule and Granule Drugs segment relates to the selling of capsule and granule drugs. The Tablet Drugs segment comprises tablet drugs. The Marketing and Promotion Services segment focuses in the marketing and promotion of services of drugs. The Others segment trades miscellaneous types of goods and drugs, other than injection drugs, capsule and granule drugs, and tablet drugs. The company was founded on August 9, 2012 and is headquartered in Hangzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
New Ray Medicine International Holding Ltd. (6108.HK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
New Ray Medicine International Holding Ltd. is an investment company, which engages in the distribution and trading of pharmaceutical products. It operates through the following business segments: Injection Drugs; Capsule and Granule Drugs; Tablet Drugs; Marketing and Promotion Services; and Others. The Injection Drugs segment includes the trading of injection drugs. The Capsule and Granule Drugs segment relates to the selling of capsule and granule drugs. The Tablet Drugs segment comprises tablet drugs. The Marketing and Promotion Services segment focuses in the marketing and promotion of services of drugs. The Others segment trades miscellaneous types of goods and drugs, other than injection drugs, capsule and granule drugs, and tablet drugs. The company was founded on August 9, 2012 and is headquartered in Hangzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free